Cancer researchers team up against deadliest brain tumors in children

The Lilabean Foundation for Pediatric Brain Cancer raises $900K

The Lilabean Foundation for Pediatric Brain Cancer Research raised $900,000 at its 13th Annual Lilabean Foundation Fall Ball, held on Saturday, November 2. Proceeds from the Fall Ball will directly fund groundbreaking research initiatives focused on discovering new treatments and improving survival rates for children fighting pediatric brain cancer.

November 22, 2024

Vol.50 No.44

In Brief

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

In Brief

Cigall Kadoch wins $250,000 Blavatnik National Award

Cigall Kadoch was named the laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences for her work in cancer biology.

September 20, 2024

Vol.50 No.35

In Brief

Washington University in St. Louis receives $2M from CureSearch for pediatric brain cancer phase I study

CureSearch for Children’s Cancer will award $2 million in funding to support a phase I clinical trial in 24 children and young adults with recurrent brain tumors.

September 06, 2024

Vol.50 No.33

In Brief

Cheng-Chia Wu joins Fralin Biomedical Research Institute at Virginia Tech Carilion

Cheng-Chia “Fred” Wu, a physician-scientist who treats brain tumors in children, has joined Virginia Tech to bring his expertise in focused ultrasound cancer research to the Fralin Biomedical Research Institute at Virginia Tech Carilion.

August 09, 2024

Vol.50 No.32

Drugs & Targets

FDA approves Voranigo for grade 2 IDH-mutant glioma

FDA has approved Voranigo (vorasidenib), an isocitrate dehydrogenase-1 and isocitrate dehydrogenase-2 inhibitor, for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.

August 09, 2024

Vol.50 No.32

Cancer researchers team up against deadliest brain tumors in children

YOU MAY BE INTERESTED IN

The Lilabean Foundation for Pediatric Brain Cancer raises $900K

SU2C announces grants supporting research in six cancer types

Cigall Kadoch wins $250,000 Blavatnik National Award

Washington University in St. Louis receives $2M from CureSearch for pediatric brain cancer phase I study

Cheng-Chia Wu joins Fralin Biomedical Research Institute at Virginia Tech Carilion

FDA approves Voranigo for grade 2 IDH-mutant glioma

Renew today!

Subscriber content

Never miss an issue!

Login